From bortezomib to other inhibitors of the proteasome and beyond.
about
Spotlight on ixazomib: potential in the treatment of multiple myelomaDeep sea as a source of novel-anticancer drugs: update on discovery and preclinical/clinical evaluation in a systems medicine perspectiveKnow the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemiaRegulation of the proteasome by ATP: implications for ischemic myocardial injury and donor heart preservationMagic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meetingTrial Watch: Proteasomal inhibitors for anticancer therapyBoron Induces Lymphocyte Proliferation and Modulates the Priming Effects of Lipopolysaccharide on MacrophagesDeubiquitinases (DUBs) and DUB inhibitors: a patent reviewAssembly of an Evolutionarily Conserved Alternative Proteasome Isoform in Human Cells.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma.Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits.Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and MethotrexateEffect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting.Targeted inhibition of the COP9 signalosome for treatment of cancerRegulation of metformin response by breast cancer associated gene 2.Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials.A reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cellsModulation of NF-κB Signaling as a Therapeutic Target in Autoimmunity.Clinical relevance of autophagic therapy in cancer: Investigating the current trends, challenges, and future prospects.Proteasome inhibitors induce AMPK activation via CaMKKβ in human breast cancer cells.Synthesis, bioactivity, docking and molecular dynamics studies of furan-based peptides as 20S proteasome inhibitors.L-Ornithine Schiff base-copper and -cadmium complexes as new proteasome inhibitors and apoptosis inducers in human cancer cells.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Bax is involved in the anticancer activity of Velcade in colorectal cancer.Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors.Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome.A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells.Positioning of proteasome inhibitors in therapy of solid malignancies.Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma.Systemic Proteasome Inhibition Induces Sustained Post-stroke Neurological Recovery and Neuroprotection via Mechanisms Involving Reversal of Peripheral Immunosuppression and Preservation of Blood-Brain-Barrier Integrity.P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.Endoplasmic reticulum-retained podocin mutants are massively degraded by the proteasome.Proteasome inhibitor MG132 induces thyroid cancer cell apoptosis by modulating the activity of transcription factor FOXO3a.Selective cytotoxicity of the herbal substance acteoside against tumor cells and its mechanistic insights.Tethered polymer nanoassemblies for sustained carfilzomib release and prolonged suppression of proteasome activity.
P2860
Q26774440-6C984A7A-5FEA-4AB7-AF30-C2D2FD7015DBQ26776294-613A9EEC-FA29-4DE3-A59B-3821199536C5Q26781895-FA2DE6F9-8217-4B97-A08A-33BBEE5F3A37Q27000202-390DBC56-7563-42E1-8042-6CB481CD4D8BQ28075816-ACC2DDD0-4E6D-44BB-9202-EC3AD8C1BB8CQ28082910-39467582-BAA1-4D5F-A868-3BB775AF2040Q28550486-C032ADD6-C63D-4E45-B5E9-03F9E6960DD6Q28834608-AC130A05-F627-40A9-8F97-A4B1CCDCB017Q34519129-A9C002F9-E721-4234-8B3D-A42E25765296Q34788381-30F68A56-A188-4EA8-918F-F91C71833319Q35005510-D4B097EB-A6BA-454C-8751-F8B4ED243215Q35434111-98D45B3A-383A-47D5-AAB0-DC93EEDD1C39Q35863135-FBAF30A7-7151-4DC6-A402-F421E330A121Q36150369-4E081F27-1F6F-4555-A05B-E9FB5A86F369Q36255777-75BE5F2D-7859-4547-B72E-A06051235AD6Q36893329-D110F130-09CF-40CA-9EFB-62CD3448CBC3Q37364323-F23A5AC8-4CFB-499B-881C-B7A28594C2DFQ37448089-90835CE7-8C01-4668-A885-B4AA2D774710Q38258843-B035F9A5-3A7F-4634-B4CD-AE36E600465DQ38444221-5C9DD1C7-17B7-429A-8283-2A8B86FDCD37Q38644746-47322CCC-8698-4347-B884-89A2BF49FE5DQ38689955-88DB26D0-D235-4397-AD23-6926496D7E09Q38847725-806BB222-869B-43DC-96EE-B6128120A852Q38914094-87991E76-B639-4C6E-A98D-742DB80BDE4AQ38932916-AF0E03C3-9040-4BCD-BD4F-A0F0F0461D5FQ39234159-F7D6B88F-4A05-41A7-9B8F-2001428E6643Q41623743-2BE228CC-9BFE-4016-ABB8-6D78F5479835Q41914993-37D4BA2A-D4D0-4380-9D33-BEF6E1122996Q42910903-C59879BE-D026-4A24-A0D2-3F2DABBCEDD2Q45051052-87126416-719D-48C2-99CD-67D9E029880EQ47114223-1308D26F-81E7-45E5-82A3-770156909295Q47353792-F9258C97-FF02-4CC7-82A6-94CF4A14F2FCQ47631097-1E1CD21E-589D-483A-8FA0-A888CA69484EQ47784917-901A5A0F-FC03-4912-9431-F73CFD13F768Q48451321-62AC6754-3D15-4BCE-B45C-0CEE6C8FAC3AQ48943059-F309A789-23B8-4FA7-B3F9-E41B6D431793Q49571788-794E7755-F81E-4EA8-BC49-DDE722B0B359Q51129826-805086D0-B274-488B-BB6A-F9C8842BF9AEQ52673808-4F1F0022-18EC-400C-BD46-44BC35F2D054Q52856824-69C429EB-E4D4-4D0A-B0B0-7B9257C3FF67
P2860
From bortezomib to other inhibitors of the proteasome and beyond.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
From bortezomib to other inhibitors of the proteasome and beyond.
@en
type
label
From bortezomib to other inhibitors of the proteasome and beyond.
@en
prefLabel
From bortezomib to other inhibitors of the proteasome and beyond.
@en
P2093
P2860
P1476
From bortezomib to other inhibitors of the proteasome and beyond.
@en
P2093
Bharati Mitra
Christine Neslund-Dudas
Daniela Buac
Fathima Rani Kona
Q Ping Dou
Rahul Deshmukh
Sara Schmitt
Zhen Zhang
P2860
P304
P356
10.2174/1381612811319220012
P577
2013-01-01T00:00:00Z